2025
Gonadotropin-releasing hormone antagonists: a prompt to early use in the hormonal treatment of gynecologic disease
Taylor H. Gonadotropin-releasing hormone antagonists: a prompt to early use in the hormonal treatment of gynecologic disease. Fertility And Sterility 2025, 123: 1012-1013. PMID: 40164377, DOI: 10.1016/j.fertnstert.2025.03.025.Peer-Reviewed Original Research
2015
Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study
Miller VM, Jenkins GD, Biernacka JM, Heit JA, Huggins GS, Hodis HN, Budoff MJ, Lobo RA, Taylor HS, Manson JE, Black DM, Naftolin F, Harman SM, de Andrade M. Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. Physiological Genomics 2015, 48: 33-41. PMID: 26508701, PMCID: PMC4757027, DOI: 10.1152/physiolgenomics.00029.2015.Peer-Reviewed Original ResearchConceptsCarotid artery intima-medial thicknessKronos Early Estrogen Prevention StudyMenopausal hormone treatmentCoronary arterial calcificationInnate immunity pathwaysIntima-medial thicknessImmunity pathwaysArterial calcificationPrevention StudySingle nucleotide polymorphismsOral conjugated equine estrogenConjugated equine estrogensTreatment effectsAgatston unitsPlacebo pillsEquine estrogensTreatment outcomesHormonal statusTreatment groupsParticipants 4Hormone treatmentCardiovascular phenotypesPharmacogenomic effectsYr changesEstrogen
2012
Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study
Miller VM, Petterson TM, Jeavons EN, Lnu AS, Rider DN, Heit JA, Cunningham JM, Huggins GS, Hodis HN, Budoff MJ, Santoro N, Hopkins PN, Lobo RA, Manson JE, Naftolin F, Taylor HS, Harman SM, de Andrade M. Genetic polymorphisms associated with carotid artery intima-media thickness and coronary artery calcification in women of the Kronos Early Estrogen Prevention Study. Physiological Genomics 2012, 45: 79-88. PMID: 23188791, PMCID: PMC3546410, DOI: 10.1152/physiolgenomics.00114.2012.Peer-Reviewed Original ResearchConceptsCarotid artery intima-media thicknessKronos Early Estrogen Prevention StudyMenopausal hormone treatmentCoronary artery calcificationArtery intima-media thicknessIntima-media thicknessCardiovascular diseaseArtery calcificationSingle nucleotide polymorphismsPrevention StudyProgression of CVDSubclinical cardiovascular diseaseInnate immunity pathwaysMultiple testingAgatston unitsCAC scoreWaist circumferenceThrombosis riskPulse pressureClinical trialsHormone treatmentLogistic regressionImmunity pathwaysGenetic polymorphismsCandidate gene variations
2011
Timing and Duration of Menopausal Hormone Treatment May Affect Cardiovascular Outcomes
Harman SM, Vittinghoff E, Brinton EA, Budoff MJ, Cedars MI, Lobo RA, Merriam GR, Miller VM, Naftolin F, Pal L, Santoro N, Taylor HS, Black DM. Timing and Duration of Menopausal Hormone Treatment May Affect Cardiovascular Outcomes. The American Journal Of Medicine 2011, 124: 199-205. PMID: 21396500, PMCID: PMC3107840, DOI: 10.1016/j.amjmed.2010.09.021.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCardiovascular SystemCoronary DiseaseDrug Administration ScheduleEstrogen Replacement TherapyEstrogensFemaleHumansMiddle AgedPostmenopausePrecision MedicineProgestinsRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsThromboembolismTime FactorsWomen's HealthConceptsMenopausal hormone treatmentCoronary heart disease riskHeart disease riskHormone treatmentExcess coronary heart disease riskWomen's Health Initiative hormone trialsDisease riskBeneficial effectsEstrogen-alone trialCoronary heart diseaseYears of treatmentNet harmTreatment-related risksRoute of administrationCurrent FoodShort durationDrug Administration recommendationsDisease incidence ratesWHI dataWHI estrogenWHI findingsCardiovascular outcomesProgestin trialMenopausal symptomsRisk ratio
2010
Peripheral microvascular responses to norepinephrine in women with orthostatic intolerance
Wenner M, Taylor H, Stachenfeld N. Peripheral microvascular responses to norepinephrine in women with orthostatic intolerance. The FASEB Journal 2010, 24: 991.17-991.17. DOI: 10.1096/fasebj.24.1_supplement.991.17.Peer-Reviewed Original ResearchCumulative stress indexVasoconstrictor responsesAdrenergic responseMaximal lower body negative pressureLower body negative pressurePeripheral microvascular responseEffects of estradiolBody negative pressureFemale sex hormonesSkin blood flowEndogenous E2GnRH antagonistNE infusionDaily administrationMicrovascular responsesCutaneous microvasculatureOrthostatic intoleranceOrthostatic toleranceSex hormonesBlood flowSkin microvasculatureAdrenergic stimulationDay 4Hormone treatmentDay 13
2007
Exogenous oestradiol and progesterone administration does not cause oedema in healthy young women
Stachenfeld NS, Taylor HS. Exogenous oestradiol and progesterone administration does not cause oedema in healthy young women. Clinical Endocrinology 2007, 66: 410-418. PMID: 17302877, DOI: 10.1111/j.1365-2265.2007.02748.x.Peer-Reviewed Original ResearchConceptsExtracellular fluid volumeTranscapillary albumin escape rateGonadotropin-releasing hormone antagonistPmol/Plasma renin activitySerum aldosterone concentrationHealthy young womenAlbumin escape rateRenin activityAldosterone concentrationGnRH antagonistHealthy womenProgesterone administrationExogenous oestradiolIntravascular volumeHormone antagonistProgesterone increaseDay 2Day 5Hormone treatmentOestradiolDay 13Extravascular componentOncotic pressureYoung women
2004
The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition
Naftolin F, Taylor HS, Karas R, Brinton E, Newman I, Clarkson TB, Mendelsohn M, Lobo RA, Judelson DR, Nachtigall LE, Heward CB, Hecht H, Jaff MR, Harman SM. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertility And Sterility 2004, 81: 1498-1501. PMID: 15193467, DOI: 10.1016/j.fertnstert.2004.02.095.Peer-Reviewed Original Research
2003
Oestrogen effects on urine concentrating response in young women
Stachenfeld NS, Taylor HS, Leone CA, Keefe DL. Oestrogen effects on urine concentrating response in young women. The Journal Of Physiology 2003, 552: 869-880. PMID: 12923212, PMCID: PMC2343447, DOI: 10.1113/jphysiol.2003.046920.Peer-Reviewed Original ResearchConceptsAVP infusionRenal sensitivityHormone treatmentDistal tubular sodium reabsorptionRenal free water clearanceRenal fluid retentionTubular sodium reabsorptionFree water clearancePlasma AVP concentrationArginine vasopressin releaseRate of clearancePhysiological rangeOE2 treatmentSodium excretionGnRHa administrationSodium reabsorptionEstrogen effectsEstrogen treatmentFluid retentionLeuprolide acetateWater clearanceRenal waterAVP concentrationVasopressin releaseUrine osmolality
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply